Compare PKE & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | DMAC |
|---|---|---|
| Founded | 1954 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.2M | 428.6M |
| IPO Year | 1994 | 2018 |
| Metric | PKE | DMAC |
|---|---|---|
| Price | $30.39 | $6.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 235.6K | 212.6K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $79.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.41 | $3.28 |
| 52 Week High | $29.85 | $10.42 |
| Indicator | PKE | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 31.54 |
| Support Level | $17.99 | $5.20 |
| Resistance Level | N/A | $6.29 |
| Average True Range (ATR) | 1.30 | 0.50 |
| MACD | 0.16 | -0.03 |
| Stochastic Oscillator | 82.55 | 4.63 |
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.